It is critical that applicants follow the instructions in the Application Guide (SF424 (R&R) Application Guide, eRA Commons Administrative Supplement User Guide or PHS 398 Application Guide, as appropriate) except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information

The Center to Reduce Cancer Health Disparities (CRCHD) of the National Cancer Institute (NCI), in partnership with the NCI Office of Cancer Centers (OCC), announces this opportunity to compete for administrative supplements to the Cancer Center Support Grants (CCSGs; P30s) for NCI-designated Cancer Centers to each recruit a Community Health Educator (CHE). The purpose of this supplement opportunity is to strengthen community outreach capacity at NCI-designated cancer centers (CCs) by working through the National Outreach Network (NON). It is expected that NON CHEs, located at CCs, will enhance dissemination of culturally appropriate, evidence-based cancer information that is tailored to the specific needs and expectations of underserved communities including rural and racial/ethnic populations (e.g., African American/Black, American Indian/Alaska Native, Asian, Hispanic/Latino, Native Hawaiian/Other Pacific Islander).

The goals of the NON are to: 1) enhance NCI-supported cancer health disparities (CHD) research efforts through culturally tailored education/outreach to underserved communities; 2) enhance the dissemination of culturally appropriate, evidence-based cancer information to underserved communities; and 3) adapt, implement, and assess culturally tailored education/outreach activities that address local and regional CHD issues. NON’s activities to date, suggest that the integration of CHE-facilitated community education and outreach within NCI-supported research programs is feasible and can enhance NCI’s and the CCs' abilities to reach underserved communities with culturally appropriate information about cancer and cancer-related health outcomes.

Through the NON and this FOA, the NCI seeks to achieve the following objectives:

• Integrate NON CHEs within the research and outreach efforts of the cancer centers and the communities in their catchment areas;
• Plan, conduct, and assess CHE-facilitated community education and outreach, aligned with NCI and cancer center research and outreach priorities, within underserved communities, both locally and regionally; and
• Strengthen partnerships/collaborations with key NCI-sponsored academic, research, community, and regional partners to enhance NCI’s ability to effectively reach underserved communities with tailored cancer information and to also foster community engagement in research.

Since 2010, the CRCHD has managed the NON, a national network of CHEs, located within NCI-funded cancer research programs. The program seeks to enhance the integration of underserved communities into the research and mission of NCI and strengthen NCI’s responsiveness to the cancer information needs of underserved communities. Access and engagement of underserved communities is also facilitated by close linkage of NON CHEs with the Geographic Management of Cancer Health Disparities Program (GMaP) hubs and the CHEs from the Partnerships to Advance Cancer Health Equity (PACHE). It is expected that the close affiliation of NON CHEs with GMaP, PACHE, and other NCI-research programs will further strengthen the ability of NCI and the CCs to reach underserved communities through region-based community education/outreach activities to disseminate cancer information aligned with NCI's research priorities.

NON, in collaboration with research and community partners, has developed, implemented, and assessed a broad range of culturally tailored community outreach activities, including Screen to Save (S2S): NCI Colorectal Cancer Outreach and Screening Initiative (for more information, see section below on Screen to Save). S2S outreach efforts have focused on increasing awareness and knowledge regarding colorectal cancer. Many efforts have also concentrated on improving community engagement in clinical research focused on prevention, early detection, and treatment trials. This administrative supplement opportunity specifically targets NCI-designated CCs as eligible candidates for this award and seeks to build and expand upon existing CC resources and partner engagement.

Eligibility Requirements

This funding opportunity utilizes NCI-designated CCs (P30). Current Principal Investigators (PIs) of active P30 cancer center grants may apply for administrative supplements provided all the following conditions are met:

• The PI designated for the administrative supplement request must also be the PI of the parent grant.
• The focus of the administrative supplement must align with the research priorities of the original ( parent ) CC grant.
• The PI may designate a Project Director (PD) to oversee the supplement. A PD should be a mid-to-senior level scientist with appropriate institutional investment and support and be willing to work collaboratively, locally and regionally, with GMaP/PACHE investigators.
• Co-PIs are not allowed.

The current supplement opportunity provides support for one full-time equivalent (FTE) NON CHE to be located at the grantee site. The focus of the NON CHE will be to conduct specific outreach and education activities that address cancer prevention and control in the target populations within the communities of the CC’s catchment area. To extend the CC's reach beyond its catchment area, it is expected that the CHE will establish a partnership with and compliment the work of the key personnel of the Community Outreach and Engagement (COE) component of the CCSG or other personnel engaged in community outreach. In this way, the CHE becomes a critical connector for linking underserved communities to state-of-the-art research, NCI priorities and resources through coordinated community education and outreach activities. It is required that the application describe its existing and future local, regional, and/or national community partners that will be engaged. For more details on the CCSG, please refer to PAR-17-095. It is expected that the CC PI and/or designated project director at the CC will support the integration of the CHE within the CC and community and facilitate connections/linkages between the CHE and regional GMaP and PACHE activities.

In the application, it is a requirement to propose activities and strategies for racially/ethnically diverse communities to address how an increased understanding, knowledge and participation in Clinical Trials (CTs) will be implemented. Additionally, CCs will have the opportunity to choose between two initiatives, focusing on either colorectal cancer or HPV vaccination. The role of the CHE should be clearly described and the proposal must illustrate how the activities and strategies will be achieved and measured. Enhancing participation of underserved populations, including racial/ethnic minorities and rural populations, into clinical cancer research is particularly important to our understanding of how treatments work in different populations and is an NCI priority. For this supplement opportunity, applicants will be required to collaborate with their cancer center to facilitate the identification and referral of participants from the community into a local and/or national clinical trial. In addition, each applicant will have the option to either conduct a colorectal cancer (Screen to Save) or human papillomavirus (HPV) outreach, education, and preventive measure project. For all three initiatives, CRCHD will provide a toolkit for CHEs to culturally tailor and implement during community education/outreach activities in their respective communities. It is expected that the CHEs will work with the COE professionals, as appropriate, to adapt and align approaches used to existing evidence. The toolkits will include NCI approved health messages, a guide on how to assess participant eligibility, sample strategies for building community-wide awareness and support for project recruitment, strategies for cultivating engaged and mutually beneficial partnerships, and strategies to facilitate or improve linkages to or initiation of care. The CHE and associated personnel will identify and implement activities deemed pertinent for outreach, education and awareness. Applicants must be able to demonstrate capacity, or a plan to engage partners, for screening or vaccination linkages specific to the area of focus. Additional information is provided below on all three initiatives.

Clinical Trial (CT) Participation & Biospecimen Collection

The purpose of the CT initiative is to increase awareness and knowledge about CTs and the importance of participating in CTs among racially/ethnically diverse communities. More specifically, CHEs will be engaged in the following activities:

• Provide culturally tailored materials to educate community members regarding clinical trials.
• Implement culturally tailored education/outreach activities to enhance community members knowledge of and inquiry about locally available CTs. CHEs should work closely with the CC’s CT coordinator and participate in their CTs workgroup/committee.
• Identify and refer community members to health care providers/institutions with available CTs. This will require full knowledge of and experience with navigation to the ClinicalTrials.gov website to provide clinical matching services within the community using portable electronics (e.g., tablet, smartphone, etc.).
• Track individuals referred to health care providers/institutions for CT participation through a 3-month post-referral follow-up to determine whether individuals accepted or declined CT participation and record reasons why individuals decided not to participate in a CT.
• Collaborate with NCI Community Oncology Research Program (NCORP) to promote currently available therapeutic and prevention trials and increase the recruitment of racially/ethnically diverse populations in CTs, including biospecimen collection (https://ncorp.cancer.gov/).
• Develop and disseminate basic health literacy information to increase knowledge and awareness within racially/ethnically diverse communities about the tailoring of care and medical-decision making to the individual patient. (i.e., risk awareness, genetic predisposition).
• Communicate and disseminate best practices related to communication and dissemination of CT information for racially/ethnically diverse populations to the program-supported CHEs, the community and partners at large.

Screen to Save (S2S): NCI Colorectal Cancer (CRC) Outreach and Screening

In November of 2016, the S2S special initiative was launched. Participating sites elected to implement either Phase I or Phase II. S2S Phase I consisted of culturally-tailored educational activities focused on CRC knowledge, risk factors, and screening options while S2S Phase II included Phase I activities and linking community members to screening and follow-up care (e.g., Fecal Immunochemical Test [FIT]/Fecal Occult Blood Test [FOBT] kit distribution and/or referral for colonoscopies). Pre- and post-educational activity surveys were conducted to assess participants knowledge of CRC risk factors, screening options, and intentions to engage in healthful behaviors related to prevention of CRC for both phases. For Phase II, 3-month follow-up surveys were administered to monitor screening and follow-up care participation. For this administrative supplement, all applicants who elect to participate in S2S must engage in Phases I and II, and partner with stakeholders that can provide linkages to care.

Human Papillomavirus (HPV) Outreach and Vaccination

The HPV Outreach and Vaccination effort seeks to increase awareness and knowledge of the HPV types that can lead to cancer and uptake of the available vaccine. An additional area of focus will be on increasing awareness of disparate vaccination rates among male and female children/adolescents of underserved populations including racial/ethnic minorities and rural populations. CHEs will be given resources, including: key messages and a toolkit that should be culturally-tailored for their community; pre- and post-educational activity surveys to assess participants knowledge of HPV and the HPV vaccine; and social media messaging developed in collaboration with OCPL. CHEs must actively engage the community and provide referrals for no/low-cost HPV vaccinations and conduct 3- and 6-month follow-up surveys.

Overall, CHEs will work with the PI/PD and designated CC staff (e.g., outreach/research staff), the community, the GMaP hub (e.g., regional coordinator), and NCI programs to ensure the work is aligned with the proposed program goals.

Local Education/Outreach

• Adapt and assist with CT, S2S, and/or HPV outreach messaging and material development (e.g., curricula and brochures) to meet their catchment area/community needs culture, language, and literacy tailoring;
• Identify gaps and barriers to the integration of community education, outreach, and linkages to care within the CC and propose strategies to resolve them;
• Identify specific ways that CHE-facilitated community education/outreach can enhance the research/study recruitment and outreach efforts of the P30 CCSG, and NCI programs (e.g., NCORP), and community;
• Adapt/implement CHE-facilitated education/outreach strategies, aligned with the CC focus, and linked by NCI priorities and GMaP regional disparity issues; and
• Identify CHE-facilitated education/outreach resources and strategies for further testing, as appropriate.

Community

• Develop and maintain academic and community partnerships to enable access to and delivery of culturally appropriate, evidence-based cancer information and education to underserved communities locally and regionally; and
• Collaborate with academic, research, community and regional NCI partners to develop, implement, and assess disparities-focused education and outreach efforts linked to local, regional, and NCI research priorities.

NCI/GMaP Priorities

• Culturally adapt CT and S2S or HPV outreach materials to meet their catchment area/community needs;
• Increase awareness and adoption of NCI recommendations on cancer prevention, early detection, and treatment through regional dissemination of information and education materials;
• Disseminate relevant NCI messages, priorities, materials, programs, and research opportunities; and
• Collaboratively plan and implement with academic partners, regional and community partners, NIH/NCI-supported research partners and other NCI programs, activities to increase awareness, knowledge, and risk awareness regarding CTs and S2S or HPV.

Submission

Cancer centers (i.e., the PIs of eligible active NCI-funded P30 awards) interested in applying for this supplement opportunity are encouraged to contact the CRCHD program staff members indicated below.

Requests for these administrative supplements must be submitted to the NCI Center to Reduce Cancer Health Disparities (CRCHD)(see address below). Applications must be prepared using the current PHS 398 grant application forms (available at http://grants1.nih.gov/grants/funding/phs398/phs398.html.)

Font size restrictions apply as designated within the PHS 398 instructions. Note that the NIH Center for Scientific Review (CSR) is NOT involved in receipt and referral of these requests.

See Section VIII. Other Information for award authorities and regulations.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

All organizations administering an eligible parent award may apply for a supplement under this announcement.

Higher Education Institutions

• Public/State Controlled Institutions of Higher Education
• Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

• Hispanic-serving Institutions
• Historically Black Colleges and Universities (HBCUs)
• Tribally Controlled Colleges and Universities (TCCUs)
• Alaska Native and Native Hawaiian Serving Institutions
• Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

• Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
• Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

• Small Businesses
• For-Profit Organizations (Other than Small Businesses)

Governments

• State Governments
• County Governments
• City or Township Governments
• Special District Governments
• Indian/Native American Tribal Governments (Federally Recognized)
• Indian/Native American Tribal Governments (Other than Federally Recognized)
• Eligible Agencies of the Federal Government
• U.S. Territory or Possession

Other

• Independent School Districts
• Public Housing Authorities/Indian Housing Authorities
• Native American Tribal Organizations (other than Federally recognized tribal governments)
• Faith-based or Community-based Organizations
• Regional Organizations

This announcement is for supplements to existing projects. To be eligible, the parent award must be active, and the research proposed in the supplement must be accomplished within the competitive segment. The proposed supplement must be to provide for an increase in costs due to unforeseen circumstances. All additional costs must be within the scope of the peer reviewed and approved project.

IMPORTANT: The research proposed by the NIH grantee in the supplement application must be within the original scope of the NIH-supported grant project.

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. Since administrative supplements are made against active grants and cooperative agreements, many of these registrations may already be in place. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

• Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
• System for Award Management (SAM) (formerly CCR) Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
• NATO Commercial and Government Entity (NCAGE) Code Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
• eRA Commons - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
• Grants.gov Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration. Grants.gov registration is only required if you plan to submit using the 'Electronic Application Submission through Grants.gov' option.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons.If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Individual(s) must hold an active grant or cooperative agreement, and the research proposed in the supplement must be accomplished within the competitive segment of the active award. Individuals are encouraged to work with their organizations to develop applications for support.

For supplements to parent awards that include multiple PDs/PIs, the supplement may be requested by any or all of the PDs/PIs (in accordance with the existing leadership plan) and submitted by the awardee institution of the parent award. Do not use this administrative supplement application to add, delete, or change the PDs/PIs listed on the parent award. Visit the Multiple Program Director/Principal Investigator Policy in the SF424 (R&R) Application Guide for more information.

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

An eligible institution may only submit one (1) application.

Although the financial plans of NCI provide support for this program, administrative supplement awards pursuant to this initiative are contingent upon the availability of funds and the receipt of a sufficient number of competitively reviewed meritorious requests.

All requests must include a detailed budget and budget justification using the standard PHS 398 form budget pages.

Applicants must prepare applications using current forms in accordance with the Application Guide.

Buttons to access the online ASSIST system or to download application forms are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

All forms must be completed for the supplemental activities only and must not reflect funding or activities for the previously awarded parent award.

It is critical that applicants follow the instructions for their submission option (SF424 (R&R) Application Guide, eRA Commons Administrative Supplement User Guide or PHS 398 Application Guide, as appropriate) including Supplemental Grant Application Instructions except where instructed in this funding opportunity announcement to do otherwise. Conformance to documented requirements is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.

All page limitations applicable to the parent award as described in the Application Guide and the Table of Page Limits must be followed.

Administrative supplement requests for most single-project activity codes can be submitted using either paper or electronic submission processes. Administrative supplement requests for multi-project activity codes must be submitted using the paper submission process. See Activity Code section in Part 1 to determine if electronic submission is an option for your activity code.

Cancer centers interested in applying for this supplement opportunity are encouraged to contact the CRCHD program staff members indicated below.

Applicants submitting paper applications must use the PHS 398 Application Forms and the PHS 398 Application Guide (available at: http://grants1.nih.gov/grants/funding/phs398/phs398.html). Font size restrictions apply as designated within the PHS 398 instructions. Note that the NIH Center for Scientific Review (CSR) is NOT involved in receipt and referral of these requests.

All requests must include the following:

• Cover Letter Citing this Administrative Supplement by title, and the following information:
• PI name (must be the same as the parent grant PI or designee);
• Parent grant number and title;
• Request up to two (2) years of support and provide the amount of the requested supplement (include direct and indirect costs);
• Name and title of the institutional official; Phone, e-mail, and address information for both the PI and institutional official; and
• The cover letter should be signed by the PI and an appropriate institutional official documenting specific institutional commitment for this award, including office space for the CHE, and for the long-term sustainability of the NON CHE.
• PHS 398 Form Page 1 (Face page) MS Word PDF
• The title of the project (Box 1) should be the title of the parent grant.
• The title of the Notice Administrative Supplements to Expand NCI-supported Community Outreach Capacity through Community Health Educators (CHE) of the National Outreach Network (NON) should be cited in Box 2, and the yes box should be checked.
• The PI of the parent grant must be the PI of the supplement request.
• The remaining items on the face page should be filled out in accordance with the PHS 398 application instructions.
• PHS 398 Form Page 2 (Project Summary) MS Word PDF
• Provide the Summary of the proposed supplement (NOT the summary for the parent grant). The summary should identify the target population, note the areas of focus for the supplement activities (i.e., the proposed clinical trial(s) to be promoted, and either the Screen to Save colorectal outreach or the HPV outreach and vaccination initiative, to be implemented), and name strategies to be used to track, monitor and evaluate the efficacy/impact of the activities and/or approaches used.

Budget

• The NCI intends to commit approximately $4.9M per year to fund 28 NON CHE administrative supplements in response to this announcement.
• Although the financial plans of NCI provide support for this program, administrative supplement awards pursuant to this initiative are contingent upon the availability of funds and the receipt of a sufficient number of competitively reviewed meritorious requests.
• All requests must include a detailed budget and budget justification using the standard PHS 398 form budget pages.
• Continuation of supplement funding beyond the initial year is contingent upon scientific progress and availability of funds.
• All requests must include a detailed budget and justification using the standard PHS 398 form budget pages.

Allowable costs include:

• Salary support plus fringe benefits for the CHE, commensurate with the percent level of effort. One CHE per CC is allowed.
• Participation in up to two face-to-face meetings (e.g., annual GMaP/NON program meeting, regional meeting, or conference for presentation purposes), for which limited travel costs need to be included in the submitted budget.
• Additional costs associated with the conduct of the proposed local and regional education and outreach activities should be justified, such as participant incentives, printing/duplication costs, translation services, facility rental fees, community consultant fees, or travel to outreach events/community meetings.
• Salary, research costs, and other activities of the PI/Co-PI are not allowable under this effort.

A brief Proposal Describing the Supplemental Activities: This section should contain sufficient detail to allow assessment of the scientific merit of the proposed plans and activities, and the appropriateness of the request for supplemental funds.

• Introduction (limit half page)
• Specific Aims (limit half page)
• CHE Description (limit half page)
• CHE-facilitated Education/Outreach (limit to 3 pages)

Introduction: Describe how the proposed supplemental activities relate to the parent grant.

Specific Aims: Include a brief statement of expected impact and relevance of the CHE and CHE-facilitated education/outreach on the research and outreach efforts of the CCs, community partners, and NCI/regional priorities.

CHE Description: Describe the expertise, qualifications and relevant prior experiences, and accomplishments of the proposed CHE(s), including CHE collaborations/partnerships that will facilitate achievement of the supplement objectives. Define the roles and responsibilities of the CHE within the CC, including a description of how the CHE will be integrated within the education and outreach efforts of the CC and in the community, as well as within national/regional efforts.

CHE-Facilitated Education/Outreach (3-page limit)

Describe the proposed CHE-facilitated education and outreach program and explain how it relates to the priority areas and objectives defined in this administrative supplement program. Suitable education/outreach events may include, but not limited to, interactive community demonstrations, other small (e.g., 25-50 participants) or large scale (e.g., greater than 100 participants) community events, community/researcher forums, or one-on-one education. All education and outreach should be culturally and resource appropriate.

Address the following specific aspects:

• Describe the elements of the proposed CHE-facilitated education and outreach program, and how this program will build upon the scientific strengths of the CC, foster underserved community engagement, and align with NCI/regional priorities.
• Describe the anticipated short-term and mid-term outcomes, such as level of participation/engagement or changes in awareness, knowledge, behavioral intent, and ideally, behavior, of the CHE-facilitated education and outreach program, and potential impact of the program on the underserved communities in the local catchment area, specifically concerning S2S, HPV awareness, and CTs. Include a detailed description of the plans for a baseline assessment/plan (as appropriate), monitoring, collecting data, implementing the program, and estimating its impact.
• Describe a process for identifying education and outreach strategies, including educational resources for use, and as appropriate, for further testing.
• Identify and describe current and proposed key research, academic, clinical and community partnerships, and how these partners will be involved in the proposed education and outreach program during the supplement period. (Letters of support from partners are encouraged.)
• Describe how the education and outreach will be aligned within the region and with NCI research priorities.
• Explain how the proposed CHE-facilitated education and outreach program can be reasonably and feasibly accomplished during the supplement time period, including a timeline with milestones for the establishment and operation of the proposed activities.
• Biographical Sketch for CHE: Biosketch must adhere to the PHS 398 format and requirements (MS Word, PDF). If a CHE candidate has not yet been identified, provide a brief description of the qualifications/experience sought, and timetable for recruitment and hiring.

Instructions for Paper-based Submissions using the PHS 398 Application Forms

Applications must be prepared using the PHS 398 research grant application forms and instructions for preparing a research grant application, with the following additional guidance:

• Checklist: Select Revision in the Type of Application field.
• Face Page (Form Page 1): On the face page of the application form, note that your application is in response to a specific program announcement, and enter the title and number of this announcement.
• Research Plan: At a minimum, the Research Strategy section should be completed and must include a summary or abstract of the funded parent award or project. Other sections should also be included if they are being changed by the proposed supplement activities.
• Project/Performance Sites section (Form Page 2): Include the primary site where the proposed supplement activities will be performed. If a portion of the proposed supplement activities will be performed at any other site(s), identify the locations in the fields provided.
• Sr/Key Personnel section (Form Page 2): List the PD/PI as the first person (regardless of their role on the supplement activities). List any other Senior/Key Personnel who are being added through this supplement, or for whom additional funds are being requested through this supplement; include a biographical sketch for each.
• Budget for Entire Proposed Project Period (Form Page 5): A proposed budget should be submitted using the PHS 398 budget forms and should only include funds requested for the additional supplement activities.
• If applicable, attach documentation in the Appendix section indicating that the proposed research experience was approved by the Institutional Animal Care and Use Committee (IACUC) or human subjects Institutional Review Board (IRB) at the grantee institution. Adherence to the NIH policy for including women and minorities in clinical studies must also be ensured, if additional human subjects involvement is planned for the supplement component.

The grantee institution, on behalf of the PD/PI of the parent award, must submit the request for supplemental funds directly to the awarding component that supports the parent award. Submit a signed, typewritten original of the application, including the checklist, NCI-CRCHD@mail.nih.gov and addressed to:

Damiya E. Whitaker, Psy.D.
NCI/Center to Reduce Cancer Health Disparities
Phone: 240-276-5806
E-mail: damiya.whitaker@nih.gov

Sandra L. San Miguel, M.S.
NCI/Center to Reduce Cancer Health Disparities
Phone: 240-276-5977
E-mail: sandra.sanmiguel@nih.gov

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov.

Part I. Overview Information contains information about Key Dates and Times. Applicants are encouraged to submit electronic applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

For paper-based application submission, information on the process of receipt and determining if your application is considered on-time is described in detail in the PHS 398 Application Guide.

This initiative is not subject to intergovernmental review.

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

Applications must be submitted using the instructions specified above.

Applicants must complete all required registrations prior to submission. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues. For assistance with application submission contact the Application Submission Contacts in Section VII.

Important reminders:
For applications submitted electronically on the SF424 (R&R) Application forms, all PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form of the SF 424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the (SAM). Additional information may be found in the Application Guide.

See more tips for avoiding common errors.

Not Applicable

Administrative Supplements do not receive peer review. Instead, the administrative criteria described below will be considered in the administrative evaluation process.

The staff of the NIH awarding component will evaluate requests for a supplement to determine its overall merit. The following general criteria will be used:

Budget and Period of Support

NIH staff will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

Overall Impact

Review and Selection Process

All applications will undergo review and evaluation for scientific and technical merit by a committee of NCI staff with expertise in the disciplines pertaining to this administrative supplement. Those applications judged to be responsive to the intent of this supplement will be evaluated based on the review criteria below and prioritized accordingly. Incomplete applications will not be reviewed. Late submissions will not be accepted.

The NON CHE supplement applications should contain sufficient detail to allow assessment of the scientific merit of the proposed plans and the appropriateness of the request for supplemental funding in order to determine the relationship to the local (parent grant), regional (GMaP), and NCI research priorities addressing relevant disparities issues.

Review criteria for the supplement will include the following:

• Relevance: Is the proposed CHE-facilitated education and outreach program a reasonable extension of the research and outreach efforts of the parent grant?
• Approach: Is the expertise and experiences of the proposed CHE appropriate to achieve the objectives of the supplement? Is the proposed plan for the CHE-facilitated education and outreach program, and alignment with NCI/regional priorities appropriate to achieve the objectives of the supplement?
• Quality: Is the proposed CHE-facilitated education and outreach program adequate to enhance NCI's ability to reach underserved communities with cancer information and foster community engagement in research?
• Feasibility: Can the proposed CHE-facilitated education and outreach program be conducted with the resources and within the timeframe proposed? What is the likelihood that the proposed efforts will be sustainable and/or lead to future information and resource/best practice sharing and dissemination, and access to and engagement of underserved communities?
• Additionally, NIH staff will consider the ability of the proposed supplement activities to increase or preserve the parent award’s overall impact within the original scope of award:
• Will the administrative supplement increase or preserve the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved?
• Will the administrative supplement increase or preserve the likelihood for the program to exert a sustained, powerful influence on the research field(s) involved?

Post-Award Requirements

Annual Progress Report: The PI must submit an annual Progress Report within their RPPR, which summarizes CHE activities, outcomes, and accomplishments per the Scope of Activities. Relevant instructions will be provided by NCI/CRCHD.

Final Cumulative Report: Within 90 days after the conclusion of the supplement period, the PI/PD must submit to the NCI CRCHD Program Officials, in place of the annual progress report for that year, a Final Report summarizing CHE activities, outcomes, and accomplishments per the Scope of Activities.

In addition, each of the following criteria will be evaluated as applicable for the proposed supplement.

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, NIH staff will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, NIH staff will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

NIH staff will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

NIH staff will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Administrative supplement requests will undergo an administrative evaluation by NIH staff, but not a full peer review. Applications submitted for this funding opportunity will be assigned to the awarding component for the parent award and will be administratively evaluated using the criteria shown above.

Not Applicable

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. This may be as an NoA for the supplemental activities only; alternatively, it may be as either a revision to the current year NoA or included as part of a future year NoA. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website. When calculating the award for additional funds, NIH will 1) prorate funding if the requested budget period is adjusted at the time of award, and 2) use the institution’s current F&A rate; i.e., the rate in effect when the new funding is provided.

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person’s race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see http://www.hhs.gov/ocr/civilrights/resources/laws/revisedlep.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html; and http://www.hhs.gov/ocr/civilrights/understanding/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.

Cooperative Agreement Terms and Conditions of Award

Any supplements to Cooperative Agreements will be subject to the same Cooperative Agreement terms and conditions as the parent award.

Reporting requirements will be specified in the terms and conditions of award as applicable to the supplemental activities. In most non-competing continuation applications, the progress report and budget for the supplement must be included with, but clearly delineated from, the progress report and budget for the parent award. The progress report must include information about the activities supported by the supplement even if support for future years is not requested. Continuation of support for the supplement activities in the remaining years of the competitive segment of the grant will depend upon satisfactory review by the NIH awarding component of progress for both the parent award and the supplement project, the research proposed for the next budget period, and the appropriateness of the proposed budget for the proposed effort. This information is submitted with the Research Performance Progress Report (RPPR) and financial statements as required in the NIH Grants Policy Statement.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 Award Term and Conditions for Recipient Integrity and Performance Matters.

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten on-time submission, and post-submission issues)

Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application processes and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-945-7573

Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov

Damiya Whitaker, Psy.D.
NCI/Center to Reduce Cancer Health Disparities
Telephone: 240-276-5806
Email: damiya.whitaker@nih.gov

Sandra L. San Miguel, M.S.
NCI/Center to Reduce Cancer Health Disparities
Telephone: 240-276-5977
Email: sandra.sanmiguel@nih.gov

Not Applicable

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.